<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21740">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01956812</url>
  </required_header>
  <id_info>
    <org_study_id>IMMU-107-04</org_study_id>
    <nct_id>NCT01956812</nct_id>
  </id_info>
  <brief_title>Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan &amp; Gemcitabine vs Placebo &amp; Gemcitabine in Metastatic Pancreatic Cancer</brief_title>
  <acronym>PANCRITÂ®-1</acronym>
  <official_title>An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunomedics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunomedics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose
      gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer
      patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which
      was a gemcitabine-containing regimen).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>quality of life will be assessed over 24 months using the FACT-hepatopancreatic form</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A IMMU-107 and gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMMU-107 and low dose gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Placebo and low dose gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo and low dose gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMMU-107</intervention_name>
    <description>Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles</description>
    <arm_group_label>Arm A IMMU-107 and gemcitabine</arm_group_label>
    <other_name>90Y-clivatuzumab tetraxetan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles</description>
    <arm_group_label>Arm B Placebo and low dose gemcitabine</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine, 200 mg/m2, given weekly x 4 in both arms</description>
    <arm_group_label>Arm A IMMU-107 and gemcitabine</arm_group_label>
    <arm_group_label>Arm B Placebo and low dose gemcitabine</arm_group_label>
    <other_name>gemcitabine 200 mg/m2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas

          -  Metastatic disease

          -  Documented disease progression after 2 prior therapies for metastatic disease (one of
             which must be gemcitabine based therapy)

          -  KPS &gt;/= 70

          -  Adequate bone marrow function

          -  Adequate hepatic function

          -  Adequate renal function

        Exclusion Criteria:

          -  CNS metastatic disease

          -  Bulky disease (any single mass &gt;10 cm).

          -  &gt;Grade 2 nausea or vomiting, and/or signs of intestinal obstruction.

          -  Prior external beam irradiation to a field that includes more than 30% of the red
             bone marrow.

          -  Patients with clinically significant severe cardiorespiratory disease.

        Please consult with the clinical trial site for the full detailed list of specific
        inclusion/exclusion criteria.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wegener, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Immunomedics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dion Yeldell</last_name>
    <phone>973-605-8200</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather Horne</last_name>
    <email>hhorne@immunomedics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University Health Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pat Vandenburg</last_name>
      <phone>574-364-2974</phone>
      <email>pvandenburg@iuhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Ponce</last_name>
      <phone>206-342-6926</phone>
      <email>Leila.Ponce@vmmc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, Goldenberg DM. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer. 2012 Nov 15;118(22):5497-506. doi: 10.1002/cncr.27592. Epub 2012 May 8.</citation>
    <PMID>22569804</PMID>
  </reference>
  <reference>
    <citation>Gulec SA, Cohen SJ, Pennington KL, Zuckier LS, Hauke RJ, Horne H, Wegener WA, Teoh N, Gold DV, Sharkey RM, Goldenberg DM. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial. Clin Cancer Res. 2011 Jun 15;17(12):4091-100. doi: 10.1158/1078-0432.CCR-10-2579. Epub 2011 Apr 28.</citation>
    <PMID>21527562</PMID>
  </reference>
  <reference>
    <citation>Sharkey RM, Karacay H, Govindan SV, Goldenberg DM. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol Cancer Ther. 2011 Jun;10(6):1072-81. doi: 10.1158/1535-7163.MCT-11-0115. Epub 2011 Apr 5.</citation>
    <PMID>21467164</PMID>
  </reference>
  <reference>
    <citation>Tokh M, Bathini V, Saif MW. First-line treatment of metastatic pancreatic cancer. JOP. 2012 Mar 10;13(2):159-62. Review.</citation>
    <PMID>22406590</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Newsome G, Liu D, Goldenberg DM. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol Cancer. 2013 Nov 20;12(1):143. doi: 10.1186/1476-4598-12-143.</citation>
    <PMID>24257318</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer. 2013 Feb 1;119(3):522-8. doi: 10.1002/cncr.27762. Epub 2012 Aug 16.</citation>
    <PMID>22898932</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, Hruban RH, Goldenberg DM. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2786-94. doi: 10.1158/1055-9965.EPI-10-0667. Epub 2010 Sep 1.</citation>
    <PMID>20810605</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Goldenberg DM, Karacay H, Rossi EA, Chang CH, Cardillo TM, McBride WJ, Sharkey RM. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res. 2008 Jun 15;68(12):4819-26. doi: 10.1158/0008-5472.CAN-08-0232.</citation>
    <PMID>18559529</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma. Clin Cancer Res. 2007 Dec 15;13(24):7380-7.</citation>
    <PMID>18094420</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol. 2006 Jan 10;24(2):252-8. Epub 2005 Dec 12.</citation>
    <PMID>16344318</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Modrak DE, Schutsky K, Cardillo TM. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int J Cancer. 2004 Apr 20;109(4):618-26.</citation>
    <PMID>14991585</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Schutsky K, Modrak D, Cardillo TM. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3929S-37S.</citation>
    <PMID>14506191</PMID>
  </reference>
  <reference>
    <citation>Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer. 2002 Jan 20;97(3):386-92.</citation>
    <PMID>11774294</PMID>
  </reference>
  <reference>
    <citation>Cardillo TM, Ying Z, Gold DV. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res. 2001 Oct;7(10):3186-92.</citation>
    <PMID>11595713</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Cardillo T, Goldenberg DM, Sharkey RM. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):147-54.</citation>
    <PMID>11418312</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Cardillo T, Vardi Y, Blumenthal R. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4. Int J Cancer. 1997 May 16;71(4):660-7.</citation>
    <PMID>9178823</PMID>
  </reference>
  <reference>
    <citation>Mariani G, Molea N, Bacciardi D, Boggi U, Fornaciari G, Campani D, Salvadori PA, Giulianotti PC, Mosca F, Gold DV, et al. Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Cancer Res. 1995 Dec 1;55(23 Suppl):5911s-5915s.</citation>
    <PMID>7493369</PMID>
  </reference>
  <reference>
    <citation>Alisauskus R, Wong GY, Gold DV. Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer. Cancer Res. 1995 Dec 1;55(23 Suppl):5743s-5748s.</citation>
    <PMID>7493339</PMID>
  </reference>
  <reference>
    <citation>Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer. 1994 Apr 15;57(2):204-10.</citation>
    <PMID>7512537</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clivatuzumab tetraxetan</keyword>
  <keyword>90Y-clivatuzumab tetraxetan</keyword>
  <keyword>IMMU-107</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
